Clinical Trial Update: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) [Phase 2]

View source ↗

Summary

This update describes a Phase 2 study of tirabrutinib (ONO-4059) in patients with primary central nervous system lymphoma, including refractory PCNSL, with the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING